Filing Flows › Alnylam Pharmaceuticals (ALNY) › Q2 2026 › vs Q2 2025
Alnylam Pharmaceuticals (ALNY) Q2 2026 vs Q2 2025 (year over year)
Alnylam Pharmaceuticals's revenue rose $517M (+67%) from $774M in Q2 2025 to $1.3B in Q2 2026. The biggest changes: Net product revenues +$560M (+91%); ONPATTRO −$34.1M (-65%); Net revenues from collaborations −$14.3M (-23%). Operating margin 17.9% against -2.1% (+20.0 pts).
Alnylam Pharmaceuticals, Q2 2026: revenue $1.3B (+67% year over year), operating margin 17.9%, net earnings $164M. The chart draws each line against Q2 2025, the increases inside each band.
Margins
| Q2 2026 | Q2 2025 | Change | |
|---|---|---|---|
| Operating margin | 17.9% | -2.1% | +20.0 pts |
| Net margin | 12.7% | -9.3% | +22.1 pts |
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| AMVUTTRA | $1.0B | $492M | $520M | +106% |
| GIVLAARI | $89.8M | $80.8M | $8.9M | +11% |
| Royalty revenue | $71.7M | $40.0M | $31.7M | +79% |
| Net product revenues | $1.2B | $613M | $560M | +91% |
| OXLUMO | $52.1M | $46.9M | $5.2M | +11% |
| Net revenues from collaborations | $47.2M | $61.5M | −$14.3M | -23% |
| ONPATTRO | $18.5M | $52.5M | −$34.1M | -65% |
| Revenue | $1.3B | $774M | $517M | +67% |
| Operating profit | $231M | −$16.2M | $248M | — |
| Costs & expenses | $1.1B | $790M | $270M | +34% |
| Pre-tax earnings | $178M | −$41.3M | $219M | — |
| Other expense, net | $53.6M | $25.1M | $28.5M | +114% |
| Cost of revenue | $298M | $142M | $156M | +110% |
| Research & development | $413M | $324M | $89.5M | +28% |
| SG&A | $348M | $323M | $24.6M | +8% |
| Net earnings | $164M | −$72.2M | $237M | — |
| Income tax | $13.3M | $30.9M | −$17.6M | -57% |
Questions
How much did Alnylam Pharmaceuticals's revenue grow year over year in Q2 2026?
Alnylam Pharmaceuticals's revenue rose $517M (+67%) from $774M in Q2 2025 to $1.3B in Q2 2026.
What drove Alnylam Pharmaceuticals's revenue change in Q2 2026?
Net product revenues +$560M (+91%); ONPATTRO −$34.1M (-65%); Net revenues from collaborations −$14.3M (-23%).